Primary site and histology
Pathology and examination notes should identify the exact anatomic site and tumor type.
Oncology evaluation directory
Head & neck oncology
Head and Neck Cancer Evaluation
A structured review for cancers of the oral cavity, pharynx, larynx, salivary glands and related head-neck sites, with attention to airway, swallowing, nutrition, prior radiation and surgical feasibility.
Medical disclaimer: This page is informational and coordination-focused. It does not diagnose, prescribe, promise treatment suitability or replace urgent local medical care.
Clinical file logic
What the specialist needs to understand before any treatment discussion.
Head and neck cancer review must be site-specific. A laryngeal tumor, oral cavity tumor, nasopharyngeal carcinoma and salivary gland malignancy can require very different questions, even when the patient describes them all as “throat cancer.”
The file is organized so the physician can understand the primary site, whether the disease is local, regional or metastatic, and whether urgent airway, nutrition or infection issues need local care before travel.
HPV/p16 or EBV context
For selected sites, HPV/p16 or EBV-related information may affect interpretation and prognosis discussions.
Airway and swallowing safety
Tracheostomy, feeding tube, aspiration risk, weight loss and ability to swallow are documented.
Prior local therapy
Surgery, radiation fields, chemotherapy, immunotherapy and dates of recurrence are placed in order.
Current imaging
MRI/CT neck, PET-CT and chest imaging help define local extension, nodes and distant disease.
Reconstruction and functional goals
Speech, swallowing, pain, nutrition and appearance-related concerns are included in the clinical question.
Evaluation matrix
How the case is reviewed without reducing it to a diagnosis name.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Anatomic clarity
The review differentiates oral cavity, oropharynx, hypopharynx, larynx, nasopharynx and salivary gland tumors.
Functional risk
Airway obstruction, bleeding, aspiration and severe malnutrition can change timing and whether travel is safe.
Radiation history
Previous radiation dose/field is critical before any discussion of re-irradiation or local control options.
Systemic context
Recurrent/metastatic disease is reviewed with prior platinum, immunotherapy and targeted options when applicable.
Documents to prepare
A complete medical file prevents delay and unrealistic expectations.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
Cuba context
How Cuba-related options are framed responsibly.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
Local safety comes first
Airway, bleeding, infection and nutrition issues must be stabilized locally before international planning.
Specialist routing is site-specific
The case may require oncology, ENT, maxillofacial surgery, radiation oncology and nutrition coordination.
No generic promise
Cuba-related discussions are framed only after the precise disease context is understood.
Options discussed in Cuba
Nimotuzumab in head and neck cancer, and the wider decision
This information is not a treatment recommendation; sequencing belongs to the oncology and radiation oncology team.
The best-known Cuba-related product in head and neck cancer is nimotuzumab (CIMAher), a monoclonal antibody directed at the epidermal growth factor receptor (EGFR). It has been studied alongside radiotherapy or chemoradiotherapy. A frequently cited feature is a milder skin-toxicity profile than other antibodies in the same class.
Some published trials report improved response when it is added to radiotherapy in advanced disease. It is licensed in Cuba for this setting and is used there alongside radiotherapy or chemoradiotherapy. International guidelines are built on their own trial programmes, so nimotuzumab is planned together with established surgery, radiotherapy and systemic therapy rather than in place of them.
What actually drives decisions in head and neck oncology is tumour subsite and stage, HPV status (particularly in oropharyngeal disease), the safety of swallowing and the airway, nutritional status, and the fields and doses of any previous radiotherapy. If these are not clear in the file, no remote review can be reliable.
HPV status
In oropharyngeal tumours, p16/HPV status changes both prognosis and treatment selection and must appear in the pathology report.
Airway and swallowing
Feeding route, tracheostomy needs and aspiration risk are practical items that determine whether travel is appropriate at all.
Prior radiotherapy
Re-irradiation of a previously treated field is a specialist decision; treated fields and cumulative dose must be documented.
When local care comes first
Do not wait for international review if urgent symptoms are present.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
- Breathing difficulty, noisy breathing or rapidly enlarging neck mass.
- Active bleeding, severe infection, inability to swallow liquids or dehydration.
- Severe uncontrolled pain, confusion or rapid decline in general condition.
Coordination pathway
From records to written next steps.
- File intakeReports, imaging, summaries and current symptoms are uploaded through the application flow.
- Quality checkThe coordination team checks readability, dates, translation needs and missing items.
- Specialist routingThe case is prepared around a clear medical question and routed to the relevant review pathway.
- Written responseThe patient receives an organized next-step explanation before travel, payment or treatment logistics are considered.
Questions
Before starting the application.
Does this page mean I am suitable for a Cuba-based treatment?
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
Can I send only a short summary?
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
Will the coordinator choose my treatment?
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
What happens if my file is incomplete?
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
Can urgent symptoms be handled through this page?
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
Related evaluation pages
Other oncology files reviewed in the same clinical directory.
Official product information
CIMAher (nimotuzumab) as licensed in Cuba
The data below are taken from the product summary approved by CECMED, the Cuban medicines regulator. They describe the product as licensed in Cuba and are not a treatment recommendation.
- Registration
- Sanitary registration 1745, registered 19 February 2002
- Manufacturer
- Center of Molecular Immunology (CIM), Havana, Cuba
- Approved indications
- Advanced squamous cell carcinoma of the head and neck in combination with radiotherapy or chemoradiotherapy, including nasopharyngeal tumours in stages III/IV with radiotherapy; adult high-grade glioma (glioblastoma multiforme and anaplastic astrocytoma) with radiotherapy; newly diagnosed paediatric high-grade glioma with radiotherapy or chemoradiotherapy; recurrent or refractory paediatric glioma as monotherapy; locally advanced, inoperable oesophageal cancer with chemoradiotherapy.
- Route and schedule
- Intravenous infusion. Adults: 200 mg once weekly for six weeks concurrently with radiotherapy or chemoradiotherapy (induction), then 200 mg every two weeks (maintenance) until clinical progression or intolerance. Paediatric recurrent or refractory glioma as monotherapy: 150 mg/m² weekly for six weeks, then every two weeks.
- Monitoring
- Must be given under the supervision of a physician experienced with intravenous medicines, with close observation during the infusion and for at least one hour afterwards. No premedication is required.
- Contraindications
- History of hypersensitivity to this product, to other products derived from mammalian cells, or to any component of the formulation.
- Reported effects
- Adverse reactions reported in pre- and post-authorisation studies include tremor, chills, nausea, headache, vomiting, anaemia and lowered or raised blood pressure.
Approval in Cuba does not mean approval in your country, and it does not mean the product is suitable for you. Eligibility is decided by the physician who reviews your complete file.
Start with the file
Submit documents before making a travel or treatment decision.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.